Tagged with Pain

Spain According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends include the fact that generics penetration in Spain has remained at a constant level for almost seven years and private…

Spain A rundown of five things to know about the healthcare and life sciences industry in Catalonia. Nestled in Northeastern Spain and bordering France, Catalonia’s capital and largest city is Barcelona. The region boasts a strong scientific output by European standards, is the birthplace of many of Spain’s pharma success stories,…

Spain Aiming to leverage European Union funds to reindustrialise its economy, the Spanish government has approved a public-private collaboration instrument to transform its health sector. The project looks to position Spain as a leader in precision medicine R&D and strengthen its healthcare sector with an investment of EUR 1.46 billion that…

Spain The deputy director of the Spanish Biosimilar Medicines Association (BioSim), Isabel del Río, comments on the current status of biosimilars in Spain – including the nearly EUR one billion in savings they bring to the system – the most important elements included in the upcoming national plan to promote the…

Spain The latest from Spanish pharma, including Rovi’s better-than-expected 2021 results thanks to its Moderna partnership, the approval of Hipra’s COVID-19 IIb clinical trials, Sanifit Therapeutics’ acquisition by Vifor Pharma, and the health technology sector’s request to the administration.   Grifols will use funds from GIC to reduce its debt (The…

Spain The Spanish pharma industry has entered the race to develop COVID-19 vaccines through an unexpected contender: an animal health company. HIPRA, headquartered in Catalonia, has received approval to begin human trials and expects to manufacture over 400 million doses in 2022.   While Spain ranks amongst the top 10 countries…

Spain The latest from Spanish pharma, including the Patent and Trademark Office’s warning of the importance of IP protection for medical advancements, Grifols’ expansion in Africa through a manufacturing plant in Nigeria, Almirall’s newest EMA approval, and COVID-19 vaccination updates.   Spanish Patent Office: medical advances would be “inconceivable” without patents…

Spain The latest from Spanish pharma, including the acquisition of PTS by a private equity group for its nanoparticle drug delivery technologies; the agreement between Esteve and Kowa to license an acute pain product currently in Phase III; and the growth of the Spanish pharma market in February after falling 4…

Spain The latest from Spanish pharma, including the wide swathe of COVID-19 syringes, vaccines, masks, and tests being produced in the country, Grifols’ Egyptian entry, a new generation of leadership at Almirall, and Esteve’s European Expansion.   Weapons “made in Spain” in the war against Covid-19 (La Razón – Spanish) https://www.larazon.es/salud/20201214/iecgoyhkpfeifhlfgpracvgtci.html…

Roundup A roundup of the latest news from Spanish pharma, including J&J’s COVID-19 vaccine trial, the latest developments at Spanish firm PharmaMar which hopes its Aplidin can be used as a treatment for COVID-19, and a new biologics plant for contract manufacturer LSNE in the city of León.   Johnson &…

Spain PharmaMar, a Spanish firm, is beginning Phase II clinical trials for its anti-tumour drug Aplidin to treat coronavirus. The firm’s stocks have soared on the news.   PharmaMar is joining the race to find a treatment for COVID1-9. The Madrid-based company that developed multiple myeloma therapy Aplidin (plitidepsin) announced that…

Belgium Ian Wilders of Spain-headquartered micro-immunotherapy specialist Labo’Life discusses the strategic importance of Belgium to the company as the country in which micro-immunotherapy was discovered and where regulation conducive to the introduction of these therapies is increasingly being introduced.   Micro-immunotherapy was the discovery of a Belgian doctor therefore it is…